VILNIUS, LT, Could 5, 2025 – (ACN Newswire) – Northway Biotech, a biopharmaceutical contract growth and manufacturing group (CDMO), as we speak introduced the growth of its protein-based and gene remedy service choices with the addition of Viral Clearance Research (VCS) capabilities. This strategic progress follows the opening of Northway Biotech’s new Gene Remedy Heart with devoted cGMP services for virus-related tasks.
With six newly established, similar BSL-2 laboratories now operational, Northway Biotech can conduct VCS packages for as much as six shoppers concurrently, considerably assuaging present market bottlenecks. Moreover, the corporate has expanded its capabilities to carry out GMP-compliant manufacturing and testing beneath BSL-3 situations, additional strengthening its service providing throughout gene remedy and broader biologics growth.
Viral Clearance Research are actually supplied each as a part of Northway Biotech’s built-in CDMO packages and as a standalone service. This flexibility permits exterior shoppers to entry VCS experience independently, with out requiring a producing settlement.
Accelerated Supply Timelines – Over One Month Sooner Than Business
Leveraging expanded infrastructure and built-in analytical capabilities, Northway Biotech is positioned to ship Viral Clearance Research considerably sooner than the present trade customary. Complete research, assessing viral removing and inactivation, can now be accomplished with closing regulatory-compliant reporting in beneath 10 weeks from initiation of mission design when two mannequin viruses are employed, and inside 12 weeks when 4 mannequin viruses are used.
“Our growth into Viral Clearance Research is a pure extension of our CDMO providers, enabling us to handle these vital research in-house and considerably cut back mission timelines for our shoppers,” stated Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech. “By investing in state-of-the-art BSL-2 and BSL-3 services, increasing technical capabilities, and additional strengthening our scientific groups, we’re uniquely positioned to ship high-quality VCS information sooner – a key benefit for shoppers advancing by way of scientific growth and regulatory approval.”
For extra data on Northway Biotech’s Viral Clearance Examine processes, service choices, and supply timelines, please full the contact type to attach with the Northway Biotech staff.
About Northway Biotech – https://www.northwaybiotech.com
Northway Biotech is a number one contract growth and manufacturing group (CDMO) supporting clients worldwide. Its extremely skilled {and professional} staff executes tasks at each stage, from cell line building and course of growth to cGMP manufacturing of biopharmaceutical merchandise. The corporate’s intensive experience and vertically built-in service providing allows fast execution of a number of tasks from its state-of-the-art GMP services whereas guaranteeing full course of and product compliance in any respect levels of analysis, growth, and business manufacturing. Northway Biotech is a privately owned firm based in 2004 and operates areas in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.
Media & Enterprise Contact:
bd@northwaybiotech.com
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Data
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
Matter: Press launch abstract
Supply: Northway Biotech
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Company Information Community
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Company Information Community.